Hopkins Biotech Podcast

Steve Doberstein: Scaling Technologies from Idea to Clinical Development

July 25, 2022 Hopkins Biotech Podcast
Hopkins Biotech Podcast
Steve Doberstein: Scaling Technologies from Idea to Clinical Development
Show Notes

Dr. Steve Doberstein has had a long career leading Research groups at a number of biotech companies, like “XOMA”- a monoclonal antibody discovery and development company, “Five Prime Therapeutics”- a protein and antibody discovery and development company, “Xencor”- a leader in protein engineering and “Exelixis”-a genomics-based drug discovery company.

Today is the founder and CEO of Kahiliholo Consulting (based in San Francisco), that supports biotech enterprises and early-stage founders. Prior his current venture, he worked for several years in Nektar Therapeutics, a company that he joined in 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of discovery research and where he has been responsible for all R&D efforts, supervising more than 300 scientists, physicians and support personnel.

Steve received his Ph.D. from the Biochemistry, Cell and Molecular Biology program at the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley.

In this episode we learned about his extensive experience in management, how to lead research groups of all sizes, develop successful R&D programs and being part of a board of directors. We also heard about his passion for biotech and how his new venture is supporting early-stage Biotech Entrepreneurs.

Hosted by Joe Varriale and Gustavo Carrizo